Results 221 to 230 of about 3,082,827 (354)

Myocardial protection by remote ischaemic pre‐conditioning is abolished in sulphonylurea‐treated diabetics undergoing coronary revascularisation

open access: yesActa Anaesthesiologica Scandinavica, 2014
E. Kottenberg   +7 more
semanticscholar   +1 more source

Myo‐Inositol Mitigates Oxidative Stress in Bovine Mammary Epithelial Cells via Activation of the SIRT5/Nrf2 Signaling Axis

open access: yesAnimal Research and One Health, EarlyView.
Myo‐inositol alleviates oxidative stress in dairy cow mammary epithelial cells via the Sirt5/Nrf2 pathway to promote mitochondrial fusion. This graphical abstract was created with BioRender.com. ABSTRACT High‐yielding dairy cows are susceptible to mammary gland oxidative stress due to prolonged intensive lactation, leading to redox imbalance.
Yufei Zhang   +8 more
wiley   +1 more source

Dexmedetomidine - A Forgotten Adjunct for Myocardial Protection. [PDF]

open access: yesAnn Card Anaesth
Abraham AS   +3 more
europepmc   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm   +2 more
wiley   +1 more source

Blood cardioplegia or custodiol for myocardial protection during valvular or aortic surgery: a propensity score adjusted comparison. [PDF]

open access: yesJ Cardiothorac Surg
Carnero-Alcazar M   +9 more
europepmc   +1 more source

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Transition from long‐term denosumab (Dmab) to parathyroid hormone‐analogs or romosozumab (Romo) might expose patients to the risk of the so‐called rebound phenomenon. Adding Romo to Dmab might represent an option in patients experiencing a fracture while on Dmab.
Giovanni Adami   +10 more
wiley   +1 more source

Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of the Phase 3, Randomized, Placebo‐Controlled SOLSTICE Study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Evaluate the efficacy and safety of guselkumab, an interleukin‐23p19‐subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor inhibitor (TNFi‐IR).
Alexis Ogdie   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy